$3.92-0.08 (-2.00%)
TriSalus Life Sciences, Inc.
TriSalus Life Sciences, Inc. in the Healthcare sector is trading at $3.92 with a market capitalization of $294M. Wall Street consensus targets $10.40 (5 analysts), implying a +165.3% move over the next 12 months. The stock is currently 51% below its 52-week high of $7.95, remaining 13.8% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 27 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $11.41Mβ | $8.90Mβ | $13.21Mβ | $11.57Mβ | $11.21M |
| Gross Profit | $9.90Mβ | $7.67Mβ | $11.44Mβ | $9.66Mβ | $9.41M |
| Operating Income | -$9.81Mβ | -$8.41Mβ | -$3.27Mβ | -$9.01Mβ | -$7.33M |
| Net Income | -$9.19Mβ | $1.54Mβ | -$9.75Mβ | -$10.81Mβ | -$8.29M |
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in th...